Targeting cell survival proteins for cancer cell death

Pharmaceuticals

Volumn 9, Issue 1, 2016, Pages

  Pandey, Manoj K ^a   Prasad, Sahdeo ^b   Tyagi, Amit Kumar ^b   Deb, Lokesh ^b   Huang, Jiamin ^b   Karelia, Deepkamal N ^a   Amin, Shantu G ^a   Aggarwal, Bharat B ^b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Apoptosis; Bcl 2 family; Chemotherapeutics; Nutraceuticals; Survival proteins; Surviving

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ALVESPIMYCIN; ANTISENSE OLIGONUCLEOTIDE; BH3 PROTEIN; CELL PROTEIN; CELL SURVIVAL PROTEIN; CHELERYTHRINE; CURCUMIN; GAMBOGIC ACID; GANETESPIB; GELDANAMYCIN; GOSSYPOL; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 90 INHIBITOR; INHIBITOR OF APOPTOSIS PROTEIN; NAVITOCLAX; NOVOBIOCIN; NUTRACEUTICAL; OBATOCLAX; OBLIMERSEN; POLYPHENON E; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; RESORCINOL; ROSMARINIC ACID; TANESPIMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENETOCLAX; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER PROGNOSIS; CANCER RESISTANCE; CARCINOGENESIS; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; DRUG STRUCTURE; DRUG TARGETING; HEMATOLOGIC MALIGNANCY; HUMAN; LEUKEMIA; LYMPHOMA; MELANOMA; MYELOMA; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; SOLID TUMOR;

EID: 84959375244     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph9010011     Document Type: Review

References (223)

1. Tsujimoto, Y.; Cossman, J.; Jaffe, E.; Croce, C.M. Involvement of the bcl-2 gene in human follicular lymphoma. Science 1985, 228, 1440-1443. [CrossRef] [PubMed]
2. Reed, J.C.; Pellecchia, M. Apoptosis-based therapies for hematologic malignancies. Blood 2005, 106, 408-418. [CrossRef] [PubMed]
3. Packham, G.; Stevenson, F.K. Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia. Immunology 2005, 114, 441-449. [CrossRef] [PubMed]
4. Kang, M.H.; Reynolds, C.P. Bcl-2 inhibitors: Targeting mitochondrial apoptotic pathways in cancer therapy. Clin. Cancer Res. 2009, 15, 1126-1132. [CrossRef] [PubMed]
5. Reed, J.C. Apoptosis-based therapies. Nat. Rev. Drug Discov. 2002, 1, 111-121. CrossRef] [PubMed]
6. Thomas, S.; Quinn, B.A.; Das, S.K.; Dash, R.; Emdad, L.; Dasgupta, S.; Wang, X.Y.; Dent, P.; Reed, J.C.; Pellecchia, M.; et al. Targeting the bcl-2 family for cancer therapy. Expert Opin. Ther. Targets 2013, 17, 61-75.[CrossRef] [PubMed]
7. Reed, J.C. Bcl-2-family proteins and hematologic malignancies: History and future prospects. Blood 2008, 111, 3322-3330. [CrossRef] [PubMed]
8. Sinicrope, F.A.; Hart, J.; Michelassi, F.; Lee, J.J. Prognostic value of bcl-2 oncoprotein expression in stage II colon carcinoma. Clin. Cancer Res. 1995, 1, 1103-1110. [PubMed]
9. Jiang, S.X.; Sato, Y.; Kuwao, S.; Kameya, T. Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas. J. Pathol. 1995, 177, 135-138. [CrossRef] [PubMed]
10. McDonnell, T.J.; Troncoso, P.; Brisbay, S.M.; Logothetis, C.; Chung, L.W.; Hsieh, J.T.; Tu, S.M.; Campbell, M.L. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 1992, 52, 6940-6944. [PubMed]
11. Joensuu, H.; Pylkkanen, L.; Toikkanen, S. Bcl-2 protein expression and long-term survival in breast cancer. Am. J. Pathol. 1994, 145, 1191-1198. [PubMed]
12. Campos, L.; Rouault, J.P.; Sabido, O.; Oriol, P.; Roubi, N.; Vasselon, C.; Archimbaud, E.; Magaud, J.P.; Guyotat, D. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993, 81, 3091-3096. [PubMed]
13. Hermine, O.; Haioun, C.; Lepage, E.; d’Agay, M.F.; Briere, J.; Lavignac, C.; Fillet, G.; Salles, G.; Marolleau, J.P.; Diebold, J.; et al. Prognostic significance of bcl-2 protein expression in aggressive non-hodgkin’s lymphoma. Groupe d’etude des lymphomes de l’adulte (gela). Blood 1996, 87, 265-272. [PubMed]
14. Grover, R.; Wilson, G.D. Bcl-2 expression in malignant melanoma and its prognostic significance. Eur. J. Surg. Oncol. 1996, 22, 347-349. [CrossRef]
15. Weller, M.; Malipiero, U.; Aguzzi, A.; Reed, J.C.; Fontana, A. Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J. Clin. Investig. 1995, 95, 2633-2643. [CrossRef] [PubMed]
16. Cimmino, A.; Calin, G.A.; Fabbri, M.; Iorio, M.V.; Ferracin, M.; Shimizu, M.; Wojcik, S.E.; Aqeilan, R.I.; Zupo, S.; Dono, M.; et al. Mir-15 and mir-16 induce apoptosis by targeting bcl2. Proc. Natl. Acad. Sci. USA 2005, 102, 13944-13949. [CrossRef] [PubMed]
17. Singh, R.; Saini, N. Downregulation of bcl2 by mirnas augments drug-induced apoptosis—a combined computational and experimental approach. J. Cell Sci. 2012, 125, 1568-1578. [CrossRef] [PubMed]
18. Rao, P.H.; Houldsworth, J.; Dyomina, K.; Parsa, N.Z.; Cigudosa, J.C.; Louie, D.C.; Popplewell, L.; Offit, K.; Jhanwar, S.C.; Chaganti, R.S. Chromosomal and gene amplification in diffuse large b-cell lymphoma. Blood 1998, 92, 234-240. [PubMed]
19. Hanada, M.; Delia, D.; Aiello, A.; Stadtmauer, E.; Reed, J.C. Bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood 1993, 82, 1820-1828. [PubMed]
20. Yano, T.; Jaffe, E.S.; Longo, D.L.; Raffeld, M. Myc rearrangements in histologically progressed follicular lymphomas. Blood 1992, 80, 758-767. [PubMed]
21. Strasser, A.; Harris, A.W.; Bath, M.L.; Cory, S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 1990, 348, 331-333. [CrossRef] [PubMed]
22. Strasser, A.; Elefanty, A.G.; Harris, A.W.; Cory, S. Progenitor tumours from Emu-bcl-2-myc transgenic mice have lymphomyeloid differentiation potential and reveal developmental differences in cell survival. EMBO J. 1996, 15, 3823-3834. [PubMed]
23. Jager, R.; Herzer, U.; Schenkel, J.; Weiher, H. Overexpression of Bcl-2 inhibits alveolar cell apoptosis during involution and accelerates c-myc-induced tumorigenesis of the mammary gland in transgenic mice. Oncogene 1997, 15, 1787-1795. [CrossRef] [PubMed]
24. Naik, P.; Karrim, J.; Hanahan, D. The rise and fall of apoptosis during multistage tumorigenesis: Down-modulation contributes to tumor progression from angiogenic progenitors. Genes Dev. 1996, 10, 2105-2116. [CrossRef] [PubMed]
25. Boise, L.H.; Gonzalez-Garcia, M.; Postema, C.E.; Ding, L.; Lindsten, T.; Turka, L.A.; Mao, X.; Nunez, G.; Thompson, C.B. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993, 74, 597-608. [CrossRef]
26. Kirsh, E.J.; Baunoch, D.A.; Stadler, W.M. Expression of bcl-2 and bcl-x in bladder cancer. J. Urol. 1998, 159, 1348-1353. [CrossRef]
27. Castilla, C.; Congregado, B.; Chinchon, D.; Torrubia, F.J.; Japon, M.A.; Saez, C. Bcl-xl is overexpressed in hormone-resistant prostate cancer and promotes survival of lncap cells via interaction with proapoptotic bak. Endocrinology 2006, 147, 4960-4967. [CrossRef] [PubMed]
28. Kozopas, K.M.; Yang, T.; Buchan, H.L.; Zhou, P.; Craig, R.W. Mcl1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to bcl2. Proc. Natl. Acad. Sci. USA 1993, 90, 3516-3520. [CrossRef] [PubMed]
29. Day, C.L.; Smits, C.; Fan, F.C.; Lee, E.F.; Fairlie, W.D.; Hinds, M.G. Structure of the BH3 domains from the p53-inducible BH3-only proteins Noxa and Puma in complex with mcl-1. J. Mol. Biol. 2008, 380, 958-971. [CrossRef] [PubMed]
30. Rinkenberger, J.L.; Horning, S.; Klocke, B.; Roth, K.; Korsmeyer, S.J. Mcl-1 deficiency results in peri-implantation embryonic lethality. Genes Dev. 2000, 14, 23-27. [PubMed]
31. Opferman, J.T.; Iwasaki, H.; Ong, C.C.; Suh, H.; Mizuno, S.; Akashi, K.; Korsmeyer, S.J. Obligate role of anti-apoptotic mcl-1 in the survival of hematopoietic stem cells. Science 2005, 307, 1101-1104. [CrossRef] [PubMed]
32. Opferman, J.T.; Letai, A.; Beard, C.; Sorcinelli, M.D.; Ong, C.C.; Korsmeyer, S.J. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 2003, 426, 671-676. [CrossRef] [PubMed]
33. Arbour, N.; Vanderluit, J.L.; Le Grand, J.N.; Jahani-Asl, A.; Ruzhynsky, V.A.; Cheung, E.C.; Kelly, M.A.; MacKenzie, A.E.; Park, D.S.; Opferman, J.T.; et al. Mcl-1 is a key regulator of apoptosis during CNS development and after DNA damage. J. Neurosci. 2008, 28, 6068-6078. [CrossRef] [PubMed]
34. Perciavalle, R.M.; Opferman, J.T. Delving deeper: Mcl-1’s contributions to normal and cancer biology. Trends Cell Biol. 2013, 23, 22-29. [CrossRef] [PubMed]
35. Beroukhim, R.; Mermel, C.H.; Porter, D.; Wei, G.; Raychaudhuri, S.; Donovan, J.; Barretina, J.; Boehm, J.S.; Dobson, J.; Urashima, M.; et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010, 463, 899-905. [CrossRef] [PubMed]
36. Glaser, S.P.; Lee, E.F.; Trounson, E.; Bouillet, P.; Wei, A.; Fairlie, W.D.; Izon, D.J.; Zuber, J.; Rappaport, A.R.; Herold, M.J.; et al. Anti-apoptotic mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev. 2012, 26, 120-125. [CrossRef] [PubMed]
37. Wei, L.H.; Kuo, M.L.; Chen, C.A.; Chou, C.H.; Cheng, W.F.; Chang, M.C.; Su, J.L.; Hsieh, C.Y. The anti-apoptotic role of interleukin-6 in human cervical cancer is mediated by up-regulation of mcl-1 through a pi 3-k/akt pathway. Oncogene 2001, 20, 5799-5809. [CrossRef] [PubMed]
38. Shigemasa, K.; Katoh, O.; Shiroyama, Y.; Mihara, S.; Mukai, K.; Nagai, N.; Ohama, K. Increased mcl-1 expression is associated with poor prognosis in ovarian carcinomas. Jpn. J. Cancer Res. 2002, 93, 542-550. [CrossRef] [PubMed]
39. Stewart, D.P.; Koss, B.; Bathina, M.; Perciavalle, R.M.; Bisanz, K.; Opferman, J.T. Ubiquitin-independent degradation of antiapoptotic mcl-1. Mol. Cell. Biol. 2010, 30, 3099-3110. [CrossRef] [PubMed]
40. Zhong, Q.; Gao, W.; Du, F.; Wang, X. Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of mcl-1 and regulates apoptosis. Cell 2005, 121, 1085-1095. [CrossRef] [PubMed]
41. Schwickart, M.; Huang, X.; Lill, J.R.; Liu, J.; Ferrando, R.; French, D.M.; Maecker, H.; O’Rourke, K.; Bazan, F.; Eastham-Anderson, J.; et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 2010, 463, 103-107. [CrossRef] [PubMed]
42. Inuzuka, H.; Shaik, S.; Onoyama, I.; Gao, D.; Tseng, A.; Maser, R.S.; Zhai, B.; Wan, L.; Gutierrez, A.; Lau, A.W.; et al. SCFFBW7 regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 2011, 471, 104-109. [CrossRef] [PubMed]
43. Rampino, N.; Yamamoto, H.; Ionov, Y.; Li, Y.; Sawai, H.; Reed, J.C.; Perucho, M. Somatic frameshift mutations in the bax gene in colon cancers of the microsatellite mutator phenotype. Science 1997, 275, 967-969. [CrossRef] [PubMed]
44. Meijerink, J.P.; Raemaekers, J.M.; Mensink, E.J. New type of t(14;18) in a non-Hodgkin’s lymphoma provides insight in molecular events in early B-cell differentiation. Br. J. Haematol. 1995, 91, 630-639. [CrossRef] [PubMed]
45. Shibue, T.; Takeda, K.; Oda, E.; Tanaka, H.; Murasawa, H.; Takaoka, A.; Morishita, Y.; Akira, S.; Taniguchi, T.; Tanaka, N. Integral role of Noxa in p53-mediated apoptotic response. Genes Dev. 2003, 17, 2233-2238.[CrossRef] [PubMed]
46. Nakano, K.; Vousden, K.H. Puma, a novel proapoptotic gene, is induced by p53. Mol. Cell 2001, 7, 683-694.[CrossRef]
47. Fulda, S.; Vucic, D. Targeting IAP proteins for therapeutic intervention in cancer. Nat. Rev. Drug Discov. 2012, 11, 109-124. [CrossRef] [PubMed]
48. Birnbaum, M.J.; Clem, R.J.; Miller, L.K. An apoptosis-inhibiting gene from a nuclear polyhedrosis virus encoding a polypeptide with cys/his sequence motifs. J. Virol. 1994, 68, 2521-2528. [PubMed]
49. Crook, N.E.; Clem, R.J.; Miller, L.K. An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. J. Virol. 1993, 67, 2168-2174. [PubMed]
50. Salvesen, G.S.; Duckett, C.S. IAP proteins: Blocking the road to death’s door. Nat. Rev. Mol. Cell Biol. 2002, 3, 401-410. [CrossRef] [PubMed]
51. Sanna, M.G.; da Silva Correia, J.; Ducrey, O.; Lee, J.; Nomoto, K.; Schrantz, N.; Deveraux, Q.L.; Ulevitch, R.J. IAP suppression of apoptosis involves distinct mechanisms: The TAK1/JNK1 signaling cascade and caspase inhibition. Mol. Cell. Biol. 2002, 22, 1754-1766. [CrossRef] [PubMed]
52. Hofer-Warbinek, R.; Schmid, J.A.; Stehlik, C.; Binder, B.R.; Lipp, J.; de Martin, R. Activation of NF-κb by XIAP, the X chromosome-linked inhibitor of apoptosis, in endothelial cells involves TAK1. J. Biol. Chem. 2000, 275, 22064-22068. [CrossRef] [PubMed]
53. Levkau, B.; Garton, K.J.; Ferri, N.; Kloke, K.; Nofer, J.R.; Baba, H.A.; Raines, E.W.; Breithardt, G. XIAP induces cell-cycle arrest and activates nuclear factor-κb: New survival pathways disabled by caspase-mediated cleavage during apoptosis of human endothelial cells. Circ. Res. 2001, 88, 282-290. [CrossRef] [PubMed]
54. Varfolomeev, E.; Vucic, D. (Un)expected roles of c-IAPs in apoptotic and nfkappab signaling pathways. Cell Cycle 2008, 7, 1511-1521. [CrossRef] [PubMed]
55. Vaux, D.L.; Silke, J. Iaps, rings and ubiquitylation. Nat. Rev. Mol. Cell. Biol. 2005, 6, 287-297. [CrossRef] [PubMed]
56. Schimmer, A.D. Inhibitor of apoptosis proteins: Translating basic knowledge into clinical practice. Cancer Res. 2004, 64, 7183-7190. [CrossRef] [PubMed]
57. Duckett, C.S.; Nava, V.E.; Gedrich, R.W.; Clem, R.J.; Van Dongen, J.L.; Gilfillan, M.C.; Shiels, H.; Hardwick, J.M.; Thompson, C.B. A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors. EMBO J. 1996, 15, 2685-2694. [PubMed]
58. Deveraux, Q.L.; Leo, E.; Stennicke, H.R.; Welsh, K.; Salvesen, G.S.; Reed, J.C. Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases. EMBO J. 1999, 18, 5242-5251. [CrossRef] [PubMed]
59. Deveraux, Q.L.; Roy, N.; Stennicke, H.R.; Van Arsdale, T.; Zhou, Q.; Srinivasula, S.M.; Alnemri, E.S.; Salvesen, G.S.; Reed, J.C. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 1998, 17, 2215-2223. [CrossRef] [PubMed]
60. Vucic, D.; Stennicke, H.R.; Pisabarro, M.T.; Salvesen, G.S.; Dixit, V.M. Ml-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr. Biol. 2000, 10, 1359-1366. [CrossRef]
61. Richter, B.W.; Mir, S.S.; Eiben, L.J.; Lewis, J.; Reffey, S.B.; Frattini, A.; Tian, L.; Frank, S.; Youle, R.J.; Nelson, D.L.; et al. Molecular cloning of ILP-2, a novel member of the inhibitor of apoptosis protein family. Mol. Cell. Biol. 2001, 21, 4292-4301. [CrossRef] [PubMed]
62. Roy, N.; Mahadevan, M.S.; McLean, M.; Shutler, G.; Yaraghi, Z.; Farahani, R.; Baird, S.; Besner-Johnston, A.; Lefebvre, C.; Kang, X.; et al. The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. Cell 1995, 80, 167-178. [CrossRef]
63. Maier, J.K.; Lahoua, Z.; Gendron, N.H.; Fetni, R.; Johnston, A.; Davoodi, J.; Rasper, D.; Roy, S.; Slack, R.S.; Nicholson, D.W.; et al. The neuronal apoptosis inhibitory protein is a direct inhibitor of caspases 3 and 7. J. Neurosci. 2002, 22, 2035-2043. [PubMed]
64. Tanaka, K.; Iwamoto, S.; Gon, G.; Nohara, T.; Iwamoto, M.; Tanigawa, N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin. Cancer Res. 2000, 6, 127-134. [PubMed]
65. Gianani, R.; Jarboe, E.; Orlicky, D.; Frost, M.; Bobak, J.; Lehner, R.; Shroyer, K.R. Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum. Pathol. 2001, 32, 119-125. [CrossRef] [PubMed]
66. Sarela, A.I.; Macadam, R.C.; Farmery, S.M.; Markham, A.F.; Guillou, P.J. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma. Gut 2000, 46, 645-650. [CrossRef] [PubMed]
67. Grabowski, P.; Kuhnel, T.; Muhr-Wilkenshoff, F.; Heine, B.; Stein, H.; Hopfner, M.; Germer, C.T.; Scherubl, H. Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br. J. Cancer 2003, 88, 115-119. [CrossRef] [PubMed]
68. Ambrosini, G.; Adida, C.; Altieri, D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 1997, 3, 917-921. [CrossRef] [PubMed]
69. Powers, M.V.; Workman, P. Inhibitors of the heat shock response: Biology and pharmacology. FEBS Lett. 2007, 581, 3758-3769. [CrossRef] [PubMed]
70. Young, J.C.; Agashe, V.R.; Siegers, K.; Hartl, F.U. Pathways of chaperone-mediated protein folding in the cytosol. Nat. Rev. Mol. Cell Biol. 2004, 5, 781-791. [CrossRef] [PubMed]
71. Scaltriti, M.; Dawood, S.; Cortes, J. Molecular pathways: Targeting hsp90-who benefits and who does not. Clin. Cancer Res. 2012, 18, 4508-4513. [CrossRef] [PubMed]
72. Banerji U. Heat shock protein 90 as a drug target: Some like it hot. Clin. Cancer Res. 2009, 15, 9-14. [CrossRef] [PubMed]
73. Whitesell, L.; Lindquist, S.L. Hsp90 and the chaperoning of cancer. Nat. Rev. Cancer 2005, 5, 761-772.[CrossRef] [PubMed]
74. Pick, E.; Kluger, Y.; Giltnane, J.M.; Moeder, C.; Camp, R.L.; Rimm, D.L.; Kluger, H.M. High hsp90 expression is associated with decreased survival in breast cancer. Cancer Res. 2007, 67, 2932-2937. [CrossRef] [PubMed]
75. Conroy, S.E.; Latchman, D.S. Do heat shock proteins have a role in breast cancer? Br. J. Cancer 1996, 74, 717-721. [CrossRef] [PubMed]
76. Taipale, M.; Jarosz, D.F.; Lindquist, S. Hsp90 at the hub of protein homeostasis: Emerging mechanistic insights. Nat. Rev. Mol. Cell Biol. 2010, 11, 515-528. [CrossRef] [PubMed]
77. Biamonte, M.A.; Van de Water, R.; Arndt, J.W.; Scannevin, R.H.; Perret, D.; Lee, W.C. Heat shock protein 90: Inhibitors in clinical trials. J. Med. Chem. 2010, 53, 3-17. [CrossRef] [PubMed]
78. Neckers, L.; Workman, P. Hsp90 molecular chaperone inhibitors: Are we there yet? Clin. Cancer Res. 2012, 18, 64-76. [CrossRef] [PubMed]
79. Sattler, M.; Liang, H.; Nettesheim, D.; Meadows, R.P.; Harlan, J.E.; Eberstadt, M.; Yoon, H.S.; Shuker, S.B.; Chang, B.S.; Minn, A.J.; et al. Structure of bcl-xl-bak peptide complex: Recognition between regulators of apoptosis. Science 1997, 275, 983-986. [CrossRef] [PubMed]
80. Willis, S.N.; Chen, L.; Dewson, G.; Wei, A.; Naik, E.; Fletcher, J.I.; Adams, J.M.; Huang, D.C. Proapoptotic bak is sequestered by mcl-1 and bcl-xl, but not bcl-2, until displaced by BH3-only proteins. Genes Dev. 2005, 19, 1294-1305. [CrossRef] [PubMed]
81. Kolluri, S.K.; Zhu, X.; Zhou, X.; Lin, B.; Chen, Y.; Sun, K.; Tian, X.; Town, J.; Cao, X.; Lin, F.; et al. A short nur77-derived peptide converts bcl-2 from a protector to a killer. Cancer Cell 2008, 14, 285-298. [CrossRef] [PubMed]
82. LaBelle, J.L.; Katz, S.G.; Bird, G.H.; Gavathiotis, E.; Stewart, M.L.; Lawrence, C.; Fisher, J.K.; Godes, M.; Pitter, K.; Kung, A.L.; et al. A stapled bim peptide overcomes apoptotic resistance in hematologic cancers. J. Clin. Investig. 2012, 122, 2018-2031. [CrossRef] [PubMed]
83. Reed, J.C.; Stein, C.; Subasinghe, C.; Haldar, S.; Croce, C.M.; Yum, S.; Cohen, J. Antisense-mediated inhibition of bcl2 protooncogene expression and leukemic cell growth and survival: Comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. Cancer Res. 1990, 50, 6565-6570. [PubMed]
84. Olie, R.A.; Zangemeister-Wittke, U. Targeting tumor cell resistance to apoptosis induction with antisense oligonucleotides: Progress and therapeutic potential. Drug Resist. Updates 2001, 4, 9-15. [CrossRef] [PubMed]
85. O’Brien, S.; Moore, J.O.; Boyd, T.E.; Larratt, L.M.; Skotnicki, A.B.; Koziner, B.; Chanan-Khan, A.A.; Seymour, J.F.; Gribben, J.; Itri, L.M.; et al. 5-year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen. J. Clin. Oncol. 2009, 27, 5208-5212. [CrossRef] [PubMed]
86. Bedikian, A.Y.; Millward, M.; Pehamberger, H.; Conry, R.; Gore, M.; Trefzer, U.; Pavlick, A.C.; DeConti, R.; Hersh, E.M.; Hersey, P.; et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The oblimersen melanoma study group. J. Clin. Oncol. 2006, 24, 4738-4745. [CrossRef] [PubMed]
87. Zangemeister-Wittke, U.; Leech, S.H.; Olie, R.A.; Simoes-Wust, A.P.; Gautschi, O.; Luedke, G.H.; Natt, F.; Haner, R.; Martin, P.; Hall, J.; et al. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xl expression efficiently induces apoptosis in tumor cells. Clin. Cancer Res. 2000, 6, 2547-2555. [PubMed]
88. Sieghart, W.; Losert, D.; Strommer, S.; Cejka, D.; Schmid, K.; Rasoul-Rockenschaub, S.; Bodingbauer, M.; Crevenna, R.; Monia, B.P.; Peck-Radosavljevic, M.; et al. Mcl-1 overexpression in hepatocellular carcinoma: A potential target for antisense therapy. J. Hepatol. 2006, 44, 151-157. [CrossRef] [PubMed]
89. Dean, N.M.; Bennett, C.F. Antisense oligonucleotide-based therapeutics for cancer. Oncogene 2003, 22, 9087-9096. [CrossRef] [PubMed]
90. Doi, K.; Li, R.; Sung, S.S.; Wu, H.; Liu, Y.; Manieri, W.; Krishnegowda, G.; Awwad, A.; Dewey, A.; Liu, X.; et al. Discovery of marinopyrrole A (maritoclax) as a selective Mcl-1 antagonist that overcomes ABT-737 resistance by binding to and targeting Mcl-1 for proteasomal degradation. J. Biol. Chem. 2012, 287, 10224-10235. [CrossRef]
91. Pandey, M.K.; Gowda, K.; Doi, K.; Sharma, A.K.; Wang, H.G.; Amin, S. Proteasomal degradation of Mcl-1 by maritoclax induces apoptosis and enhances the efficacy of ABT-737 in melanoma cells. PLoS ONE 2013, 8. [CrossRef]
92. Tzung, S.P.; Kim, K.M.; Basanez, G.; Giedt, C.D.; Simon, J.; Zimmerberg, J.; Zhang, K.Y.; Hockenbery, D.M. Antimycin a mimics a cell-death-inducing bcl-2 homology domain 3. Nat. Cell Biol. 2001, 3, 183-191. [CrossRef] [PubMed]
93. Kitada, S.; Leone, M.; Sareth, S.; Zhai, D.; Reed, J.C.; Pellecchia, M. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J. Med. Chem. 2003, 46, 4259-4264. [CrossRef] [PubMed]
94. Witham, J.; Valenti, M.R.; De-Haven-Brandon, A.K.; Vidot, S.; Eccles, S.A.; Kaye, S.B.; Richardson, A. The bcl-2/bcl-xl family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. Clin. Cancer Res. 2007, 13, 7191-7198. [CrossRef] [PubMed]
95. Hikita, H.; Takehara, T.; Shimizu, S.; Kodama, T.; Shigekawa, M.; Iwase, K.; Hosui, A.; Miyagi, T.; Tatsumi, T.; Ishida, H.; et al. The bcl-xl inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib. Hepatology 2010, 52, 1310-1321. [CrossRef] [PubMed]
96. Hann, C.L.; Daniel, V.C.; Sugar, E.A.; Dobromilskaya, I.; Murphy, S.C.; Cope, L.; Lin, X.; Hierman, J.S.; Wilburn, D.L.; Watkins, D.N.; et al. Therapeutic efficacy of ABT-737, a selective inhibitor of bcl-2, in small cell lung cancer. Cancer Res. 2008, 68, 2321-2328. [CrossRef] [PubMed]
97. Oltersdorf, T.; Elmore, S.W.; Shoemaker, A.R.; Armstrong, R.C.; Augeri, D.J.; Belli, B.A.; Bruncko, M.; Deckwerth, T.L.; Dinges, J.; Hajduk, P.J.; et al. An inhibitor of bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435, 677-681. [CrossRef] [PubMed]
98. Roberts, A.W.; Seymour, J.F.; Brown, J.R.; Wierda, W.G.; Kipps, T.J.; Khaw, S.L.; Carney, D.A.; He, S.Z.; Huang, D.C.; Xiong, H.; et al. Substantial susceptibility of chronic lymphocytic leukemia to bcl2 inhibition: Results of a phase I study of navitoclax in patients with relapsed or refractory disease. J. Clin. Oncol. 2012, 30, 488-496. [CrossRef] [PubMed]
99. Wilson, W.H.; O’Connor, O.A.; Czuczman, M.S.; LaCasce, A.S.; Gerecitano, J.F.; Leonard, J.P.; Tulpule, A.; Dunleavy, K.; Xiong, H.; Chiu, Y.L.; et al. Navitoclax, a targeted high-affinity inhibitor of bcl-2, in lymphoid malignancies: A phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 2010, 11, 1149-1159. [CrossRef]
100. Billard, C. BH3 mimetics: Status of the field and new developments. Mol. Cancer Ther. 2013, 12, 1691-1700. [CrossRef] [PubMed]
101. Yecies, D.; Carlson, N.E.; Deng, J.; Letai, A. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 2010, 115, 3304-3313. [CrossRef] [PubMed]
102. Van Delft, M.F.; Wei, A.H.; Mason, K.D.; Vandenberg, C.J.; Chen, L.; Czabotar, P.E.; Willis, S.N.; Scott, C.L.; Day, C.L.; Cory, S.; et al. The BH3 mimetic ABT-737 targets selective bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if mcl-1 is neutralized. Cancer Cell 2006, 10, 389-399. [CrossRef]
103. Lucas, K.M.; Mohana-Kumaran, N.; Lau, D.; Zhang, X.D.; Hersey, P.; Huang, D.C.; Weninger, W.; Haass, N.K.; Allen, J.D. Modulation of Noxa and mcl-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737. Clin. Cancer Res. 2012, 18, 783-795. [CrossRef] [PubMed]
104. Smoot, R.L.; Blechacz, B.R.; Werneburg, N.W.; Bronk, S.F.; Sinicrope, F.A.; Sirica, A.E.; Gores, G.J. A Bax-mediated mechanism for obatoclax-induced apoptosis of cholangiocarcinoma cells. Cancer Res. 2010, 70, 1960-1969. [CrossRef] [PubMed]
105. Konopleva, M.; Watt, J.; Contractor, R.; Tsao, T.; Harris, D.; Estrov, Z.; Bornmann, W.; Kantarjian, H.; Viallet, J.; Samudio, I.; et al. Mechanisms of antileukemic activity of the novel bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). Cancer Res. 2008, 68, 3413-3420. [CrossRef] [PubMed]
106. Pan, J.; Cheng, C.; Verstovsek, S.; Chen, Q.; Jin, Y.; Cao, Q. The BH3-mimetic GX15-070 induces autophagy, potentiates the cytotoxicity of carboplatin and 5-fluorouracil in esophageal carcinoma cells. Cancer Lett. 2010, 293, 167-174. [CrossRef]
107. Joudeh, J.; Claxton, D. Obatoclax mesylate: Pharmacology and potential for therapy of hematological neoplasms. Expert Opin. Investig. Drugs 2012, 21, 363-373. [CrossRef] [PubMed]
108. Hwang, J.J.; Kuruvilla, J.; Mendelson, D.; Pishvaian, M.J.; Deeken, J.F.; Siu, L.L.; Berger, M.S.; Viallet, J.; Marshall, J.L. Phase I dose finding studies of obatoclax (GX15-070), a small molecule pan-bcl-2 family antagonist, in patients with advanced solid tumors or lymphoma. Clin. Cancer Res. 2010, 16, 4038-4045. [CrossRef] [PubMed]
109. Hughes, C.C.; Prieto-Davo, A.; Jensen, P.R.; Fenical, W. The marinopyrroles, antibiotics of an unprecedented structure class from a marine Streptomyces sp. Org. Lett. 2008, 10, 629-631. [CrossRef] [PubMed]
110. Doi, K.; Liu, Q.; Gowda, K.; Barth, B.M.; Claxton, D.; Amin, S.; Loughran, T.P., Jr.; Wang, H.G. Maritoclax induces apoptosis in acute myeloid leukemia cells with elevated mcl-1 expression. Cancer Biol. Ther. 2014, 15. [CrossRef] [PubMed]
111. Wei, J.; Kitada, S.; Stebbins, J.L.; Placzek, W.; Zhai, D.; Wu, B.; Rega, M.F.; Zhang, Z.; Cellitti, J.; Yang, L.; et al. Synthesis and biological evaluation of apogossypolone derivatives as pan-active inhibitors of antiapoptotic B-cell lymphoma/leukemia-2 (bcl-2) family proteins. J. Med. Chem. 2010, 53, 8000-8011. [CrossRef] [PubMed]
112. Baggstrom, M.Q.; Qi, Y.; Koczywas, M.; Argiris, A.; Johnson, E.A.; Millward, M.J.; Murphy, S.C.; Erlichman, C.; Rudin, C.M.; Govindan, R. A phase II study of AT-101 (gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer. J. Thorac. Oncol. 2011, 6, 1757-1760. [CrossRef] [PubMed]
113. Wang, Z.; Song, W.; Aboukameel, A.; Mohammad, M.; Wang, G.; Banerjee, S.; Kong, D.; Wang, S.; Sarkar, F.H.; Mohammad, R.M. Tw-37, a small-molecule inhibitor of bcl-2, inhibits cell growth and invasion in pancreatic cancer. Int. J. Cancer 2008, 123, 958-966. [CrossRef] [PubMed]
114. Mohammad, R.M.; Goustin, A.S.; Aboukameel, A.; Chen, B.; Banerjee, S.; Wang, G.; Nikolovska-Coleska, Z.; Wang, S.; Al-Katib, A. Preclinical studies of TW-37, a new nonpeptidic small-molecule inhibitor of bcl-2, in diffuse large cell lymphoma xenograft model reveal drug action on both bcl-2 and mcl-1. Clin. Cancer Res. 2007, 13, 2226-2235. [CrossRef] [PubMed]
115. Zeitlin, B.D.; Joo, E.; Dong, Z.; Warner, K.; Wang, G.; Nikolovska-Coleska, Z.; Wang, S.; Nor, J.E. Antiangiogenic effect of TW37, a small-molecule inhibitor of bcl-2. Cancer Res. 2006, 66, 8698-8706. [CrossRef] [PubMed]
116. Sun, J.; Li, Z.M.; Hu, Z.Y.; Zeng, Z.L.; Yang, D.J.; Jiang, W.Q. Apogossypolone inhibits cell growth by inducing cell cycle arrest in u937 cells. Oncol. Rep. 2009, 22, 193-198. [PubMed]
117. Paoluzzi, L.; Gonen, M.; Gardner, J.R.; Mastrella, J.; Yang, D.; Holmlund, J.; Sorensen, M.; Leopold, L.; Manova, K.; Marcucci, G.; et al. Targeting bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of b-cell lymphoma. Blood 2008, 111, 5350-5358. [CrossRef] [PubMed]
118. Wei, J.; Stebbins, J.L.; Kitada, S.; Dash, R.; Placzek, W.; Rega, M.F.; Wu, B.; Cellitti, J.; Zhai, D.; Yang, L.; et al. BI-97C1, an optically pure apogossypol derivative as pan-active inhibitor of antiapoptotic B-cell lymphoma/leukemia-2 (bcl-2) family proteins. J. Med. Chem. 2010, 53, 4166-4176. [CrossRef] [PubMed]
119. Dash, R.; Azab, B.; Quinn, B.A.; Shen, X.; Wang, X.Y.; Das, S.K.; Rahmani, M.; Wei, J.; Hedvat, M.; Dent, P.; et al. Apogossypol derivative BI-97C1 (Sabutoclax) targeting mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity. Proc. Natl. Acad. Sci. USA 2011, 108, 8785-8790. [CrossRef] [PubMed]
120. Kazi, A.; Sun, J.; Doi, K.; Sung, S.S.; Takahashi, Y.; Yin, H.; Rodriguez, J.M.; Becerril, J.; Berndt, N.; Hamilton, A.D.; et al. The BH3 α-helical mimic BH3-m6 disrupts bcl-x(l), bcl-2, and mcl-1 protein-protein interactions with bax, bak, bad, or bim and induces apoptosis in a bax- and bimdependent manner. J. Biol. Chem. 2011, 286, 9382-9392. [CrossRef] [PubMed]
121. Varfolomeev, E.; Blankenship, J.W.; Wayson, S.M.; Fedorova, A.V.; Kayagaki, N.; Garg, P.; Zobel, K.; Dynek, J.N.; Elliott, L.O.; Wallweber, H.J.; et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-κb activation, and TNFα-dependent apoptosis. Cell 2007, 131, 669-681. [CrossRef] [PubMed]
122. Vince, J.E.; Wong, W.W.; Khan, N.; Feltham, R.; Chau, D.; Ahmed, A.U.; Benetatos, C.A.; Chunduru, S.K.; Condon, S.M.; McKinlay, M.; et al. IAP antagonists target ciap1 to induce TNFα-dependent apoptosis. Cell 2007, 131, 682-693. [CrossRef] [PubMed]
123. Ndubaku, C.; Varfolomeev, E.; Wang, L.; Zobel, K.; Lau, K.; Elliott, L.O.; Maurer, B.; Fedorova, A.V.; Dynek, J.N.; Koehler, M.; et al. Antagonism of c-IAP and XIAP proteins is required for efficient induction of cell death by small-molecule IAP antagonists. ACS Chem. Biol. 2009, 4, 557-566. [CrossRef] [PubMed]
124. Schimmer, A.D.; Dalili, S.; Batey, R.A.; Riedl, S.J. Targeting XIAP for the treatment of malignancy. Cell Death Differ. 2006, 13, 179-188. [CrossRef] [PubMed]
125. Li, L.; Thomas, R.M.; Suzuki, H.; De Brabander, J.K.; Wang, X.; Harran, P.G. A small molecule smac mimic potentiates trail- and TNFα-mediated cell death. Science 2004, 305, 1471-1474. [CrossRef] [PubMed]
126. Ndubaku, C.; Cohen, F.; Varfolomeev, E.; Vucic, D. Targeting inhibitor of apoptosis proteins for therapeutic intervention. Future Med. Chem. 2009, 1, 1509-1525. [CrossRef] [PubMed]
127. Sun, H.; Nikolovska-Coleska, Z.; Lu, J.; Meagher, J.L.; Yang, C.Y.; Qiu, S.; Tomita, Y.; Ueda, Y.; Jiang, S.; Krajewski, K.; et al. Design, synthesis, and characterization of a potent, nonpeptide, cell-permeable, bivalent smac mimetic that concurrently targets both the BIR2 and BIR3 domains in XIAP. J. Am. Chem. Soc. 2007, 129, 15279-15294. [CrossRef] [PubMed]
128. Petersen, S.L.; Wang, L.; Yalcin-Chin, A.; Li, L.; Peyton, M.; Minna, J.; Harran, P.; Wang, X. Autocrine TNFα signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 2007, 12, 445-456. [CrossRef] [PubMed]
129. Chai, J.; Du, C.; Wu, J.W.; Kyin, S.; Wang, X.; Shi, Y. Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature 2000, 406, 855-862. [PubMed]
130. Verhagen, A.M.; Ekert, P.G.; Pakusch, M.; Silke, J.; Connolly, L.M.; Reid, G.E.; Moritz, R.L.; Simpson, R.J.; Vaux, D.L. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000, 102, 43-53. [CrossRef]
131. Wu, G.; Chai, J.; Suber, T.L.; Wu, J.W.; Du, C.; Wang, X.; Shi, Y. Structural basis of IAP recognition by Smac/DIABLO. Nature 2000, 408, 1008-1012. [PubMed]
132. Franklin, M.C.; Kadkhodayan, S.; Ackerly, H.; Alexandru, D.; Distefano, M.D.; Elliott, L.O.; Flygare, J.A.; Mausisa, G.; Okawa, D.C.; Ong, D.; et al. Structure and function analysis of peptide antagonists of melanoma inhibitor of apoptosis (ML-IAP). Biochemistry 2003, 42, 8223-8231. [CrossRef] [PubMed]
133. Vucic, D.; Deshayes, K.; Ackerly, H.; Pisabarro, M.T.; Kadkhodayan, S.; Fairbrother, W.J.; Dixit, V.M. Smac negatively regulates the anti-apoptotic activity of melanoma inhibitor of apoptosis (ML-IAP). J. Biol. Chem. 2002, 277, 12275-12279. [CrossRef] [PubMed]
134. Fulda, S.; Wick, W.; Weller, M.; Debatin, K.M. Smac agonists sensitize for APO2L/trail- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat. Med. 2002, 8, 808-815. [CrossRef] [PubMed]
135. Schulte, T.W.; Neckers, L.M. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to hsp90 and shares important biologic activities with geldanamycin. Cancer Chemother. Pharmacol. 1998, 42, 273-279. [CrossRef] [PubMed]
136. Kim, Y.S.; Alarcon, S.V.; Lee, S.; Lee, M.J.; Giaccone, G.; Neckers, L.; Trepel, J.B. Update on hsp90 inhibitors in clinical trial. Curr. Top. Med. Chem. 2009, 9, 1479-1492. [CrossRef] [PubMed]
137. Sydor, J.R.; Normant, E.; Pien, C.S.; Porter, J.R.; Ge, J.; Grenier, L.; Pak, R.H.; Ali, J.A.; Dembski, M.S.; Hudak, J.; et al. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against hsp90. Proc. Natl. Acad. Sci. USA 2006, 103, 17408-17413. [CrossRef] [PubMed]
138. Ge, J.; Normant, E.; Porter, J.R.; Ali, J.A.; Dembski, M.S.; Gao, Y.; Georges, A.T.; Grenier, L.; Pak, R.H.; Patterson, J.; et al. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of hsp90. J. Med. Chem. 2006, 49, 4606-4615. [CrossRef] [PubMed]
139. Yang, Z.Q.; Geng, X.; Solit, D.; Pratilas, C.A.; Rosen, N.; Danishefsky, S.J. New efficient synthesis of resorcinylic macrolides via ynolides: Establishment of cycloproparadicicol as synthetically feasible preclinical anticancer agent based on hsp90 as the target. J. Am. Chem. Soc. 2004, 126, 7881-7889. [CrossRef] [PubMed]
140. Jhaveri, K.; Taldone, T.; Modi, S.; Chiosis, G. Advances in the clinical development of heat shock protein 90 (hsp90) inhibitors in cancers. Biochim. Biophys. Acta 2012, 1823, 742-755. [CrossRef] [PubMed]
141. Chiosis, G.; Timaul, M.N.; Lucas, B.; Munster, P.N.; Zheng, F.F.; Sepp-Lorenzino, L.; Rosen, N. A small molecule designed to bind to the adenine nucleotide pocket of hsp90 causes her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem. Biol. 2001, 8, 289-299. [CrossRef]
142. Caldas-Lopes, E.; Cerchietti, L.; Ahn, J.H.; Clement, C.C.; Robles, A.I.; Rodina, A.; Moulick, K.; Taldone, T.; Gozman, A.; Guo, Y.; et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc. Natl. Acad. Sci. USA 2009, 106, 8368-8373. [CrossRef] [PubMed]
143. Kasibhatla, S.R.; Hong, K.; Biamonte, M.A.; Busch, D.J.; Karjian, P.L.; Sensintaffar, J.L.; Kamal, A.; Lough, R.E.; Brekken, J.; Lundgren, K.; et al. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity. J. Med. Chem. 2007, 50, 2767-2778. [CrossRef] [PubMed]
144. Bao, R.; Lai, C.J.; Qu, H.; Wang, D.; Yin, L.; Zifcak, B.; Atoyan, R.; Wang, J.; Samson, M.; Forrester, J.; et al. CUDC-305, a novel synthetic HSP90 inhibitor with unique pharmacologic properties for cancer therapy. Clin. Cancer Res. 2009, 15, 4046-4057. [CrossRef] [PubMed]
145. Lundgren, K.; Zhang, H.; Brekken, J.; Huser, N.; Powell, R.E.; Timple, N.; Busch, D.J.; Neely, L.; Sensintaffar, J.L.; Yang, Y.C.; et al. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein hsp90. Mol. Cancer Ther. 2009, 8, 921-929. [CrossRef] [PubMed]
146. Aggarwal, B.B.; Van Kuiken, M.E.; Iyer, L.H.; Harikumar, K.B.; Sung, B. Molecular targets of nutraceuticals derived from dietary spices: Potential role in suppression of inflammation and tumorigenesis. Exp. Biol. Med. 2009, 234, 825-849. [CrossRef] [PubMed]
147. Dhillon, N.; Aggarwal, B.B.; Newman, R.A.; Wolff, R.A.; Kunnumakkara, A.B.; Abbruzzese, J.L.; Ng, C.S.; Badmaev, V.; Kurzrock, R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin. Cancer Res. 2008, 14, 4491-4499. [CrossRef] [PubMed]
148. Sonpavde, G.; Matveev, V.; Burke, J.M.; Caton, J.R.; Fleming, M.T.; Hutson, T.E.; Galsky, M.D.; Berry, W.R.; Karlov, P.; Holmlund, J.T.; et al. Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer. Ann. Oncol. 2012, 23, 1803-1808. [CrossRef] [PubMed]
149. Liu, B.; Bai, Q.X.; Chen, X.Q.; Gao, G.X.; Gu, H.T. Effect of curcumin on expression of survivin, bcl-2 and bax in human multiple myeloma cell line. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2007, 15, 762-766. [PubMed]
150. Kolettas, E.; Thomas, C.; Leneti, E.; Skoufos, I.; Mbatsi, C.; Sisoula, C.; Manos, G.; Evangelou, A. Rosmarinic acid failed to suppress hydrogen peroxide-mediated apoptosis but induced apoptosis of jurkat cells which was suppressed by bcl-2. Mol. Cell. Biochem. 2006, 285, 111-120. [CrossRef] [PubMed]
151. Ahmed, N.; Laverick, L.; Sammons, J.; Zhang, H.; Maslin, D.J.; Hassan, H.T. Ajoene, a garlic-derived natural compound, enhances chemotherapy-induced apoptosis in human myeloid leukaemia CD34-positive resistant cells. Anticancer Res. 2001, 21, 3519-3523. [PubMed]
152. Goy, A.; Hernandez-Ilzaliturri, F.J.; Kahl, B.; Ford, P.; Protomastro, E.; Berger, M. A phase I/II study of the pan bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma. Leuk. Lymphoma 2014, 55, 2761-2768. [CrossRef] [PubMed]
153. Wiechno, P.; Somer, B.G.; Mellado, B.; Chlosta, P.L.; Cervera Grau, J.M.; Castellano, D.; Reuter, C.; Stockle, M.; Kamradt, J.; Pikiel, J.; et al. A randomised phase 2 study combining ly2181308 sodium (survivin antisense oligonucleotide) with first-line docetaxel/prednisone in patients with castration-resistant prostate cancer. Eur. Urol. 2014, 65, 516-520. [CrossRef] [PubMed]
154. Sinicrope, F.A.; Penington, R.C.; Tang, X.M. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis is inhibited by bcl-2 but restored by the small molecule bcl-2 inhibitor, HA 14-1, in human colon cancer cells. Clin. Cancer Res. 2004, 10, 8284-8292. [CrossRef] [PubMed]
155. Mesri, M.; Wall, N.R.; Li, J.; Kim, R.W.; Altieri, D.C. Cancer gene therapy using a survivin mutant adenovirus. J. Clin. Investig. 2001, 108, 981-990. [CrossRef] [PubMed]
156. Arisan, E.D.; Kutuk, O.; Tezil, T.; Bodur, C.; Telci, D.; Basaga, H. Small inhibitor of bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating bcl-2 family members in MDA-MB-231 breast cancer cells. Breast Cancer Res. Treat. 2010, 119, 271-281. [CrossRef] [PubMed]
157. Raetz, E.A.; Morrison, D.; Romanos-Sirakis, E.; Gaynon, P.; Sposto, R.; Bhojwani, D.; Bostrom, B.C.; Brown, P.; Eckroth, E.; Cassar, J.; et al. A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): A report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium. J. Pediatr. Hematol. Oncol. 2013. [CrossRef]
158. Mitsiades, C.S.; Hayden, P.; Kotoula, V.; McMillin, D.W.; McMullan, C.; Negri, J.; Delmore, J.E.; Poulaki, V.; Mitsiades, N. Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to bcl-2 homology 3 domain inhibition. J. Clin. Endocrinol. Metab. 2007, 92, 4845-4852. [CrossRef] [PubMed]
159. Hansen, J.B.; Fisker, N.; Westergaard, M.; Kjaerulff, L.S.; Hansen, H.F.; Thrue, C.A.; Rosenbohm, C.; Wissenbach, M.; Orum, H.; Koch, T. Spc3042: A proapoptotic survivin inhibitor. Mol. Cancer Ther. 2008, 7, 2736-2745. [CrossRef] [PubMed]
160. Al-Karaawi, M.A. Interaction studies to evaluate 2-carboxyphenolate analogues as inhibitor of anti-apoptotic protein bcl-2. Bioinformation 2013, 9, 477-480. [CrossRef] [PubMed]
161. Kelly, R.J.; Thomas, A.; Rajan, A.; Chun, G.; Lopez-Chavez, A.; Szabo, E.; Spencer, S.; Carter, C.A.; Guha, U.; Khozin, S.; et al. A phase I/II study of sepantronium bromide (YM155, survivin suppressor) with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer. Ann. Oncol. 2013, 24, 2601-2606. [CrossRef] [PubMed]
162. Felix, S.; Sandjo, L.P.; Opatz, T.; Erkel, G. SF002-96-1, a new drimane sesquiterpene lactone from an aspergillus species, inhibits survivin expression. Beilstein J. Org. Chem. 2013, 9, 2866-2876. [CrossRef] [PubMed]
163. Shanafelt, T.D.; Call, T.G.; Zent, C.S.; Leis, J.F.; LaPlant, B.; Bowen, D.A.; Roos, M.; Laumann, K.; Ghosh, A.K.; Lesnick, C.; et al. Phase 2 trial of daily, oral polyphenon e in patients with asymptomatic, RAI stage 0 to II chronic lymphocytic leukemia. Cancer 2013, 119, 363-370. [CrossRef] [PubMed]
164. Wadegaonkar, V.P.; Wadegaonkar, P.A. Withanone as an inhibitor of survivin: A potential drug candidate for cancer therapy. J. Biotechnol. 2013, 168, 229-233. [CrossRef] [PubMed]
165. Lee, S.; Braun, C.R.; Bird, G.H.; Walensky, L.D. Photoreactive stapled peptides to identify and characterize bcl-2 family interaction sites by mass spectrometry. Methods Enzymol. 2014, 544, 25-48. [PubMed]
166. Shi, X.; Wang, D.; Ding, K.; Lu, Z.; Jin, Y.; Zhang, J.; Pan, J. GDP366, a novel small molecule dual inhibitor of survivin and Op18, induces cell growth inhibition, cellular senescence and mitotic catastrophe in human cancer cells. Cancer Biol. Ther. 2010, 9, 640-650. [CrossRef] [PubMed]
167. Real, P.J.; Cao, Y.; Wang, R.; Nikolovska-Coleska, Z.; Sanz-Ortiz, J.; Wang, S.; Fernandez-Luna, J.L. Breast cancer cells can evade apoptosis-mediated selective killing by a novel small molecule inhibitor of bcl-2. Cancer Res. 2004, 64, 7947-7953. [CrossRef] [PubMed]
168. Kaneko, M.; Nakashima, T.; Uosaki, Y.; Hara, M.; Ikeda, S.; Kanda, Y. Synthesis of tetrocarcin derivatives with specific inhibitory activity towards bcl-2 functions. Bioorg. Med. Chem. Lett. 2001, 11, 887-890. [CrossRef]
169. Chan, S.L.; Lee, M.C.; Tan, K.O.; Yang, L.K.; Lee, A.S.; Flotow, H.; Fu, N.Y.; Butler, M.S.; Soejarto, D.D.; Buss, A.D.; et al. Identification of chelerythrine as an inhibitor of bclxl function. J. Biol. Chem. 2003, 278, 20453-20456. [CrossRef] [PubMed]
170. Varadarajan, S.; Vogler, M.; Butterworth, M.; Dinsdale, D.; Walensky, L.D.; Cohen, G.M. Evaluation and critical assessment of putative mcl-1 inhibitors. Cell Death Differ. 2013, 20, 1475-1484. [CrossRef] [PubMed]
171. Lessene, G.; Czabotar, P.E.; Sleebs, B.E.; Zobel, K.; Lowes, K.N.; Adams, J.M.; Baell, J.B.; Colman, P.M.; Deshayes, K.; Fairbrother, W.J.; et al. Structure-guided design of a selective bcl-x(l) inhibitor. Nat. Chem. Biol. 2013, 9, 390-397. [CrossRef] [PubMed]
172. Wang, Z.; Goulet, R., 3rd; Stanton, K.J.; Sadaria, M.; Nakshatri, H. Differential effect of anti-apoptotic genes bcl-xl and c-flip on sensitivity of mcf-7 breast cancer cells to paclitaxel and docetaxel. Anticancer Res. 2005, 25, 2367-2379. [PubMed]
173. Wu, T.Y.; Wagner, K.W.; Bursulaya, B.; Schultz, P.G.; Deveraux, Q.L. Development and characterization of nonpeptidic small molecule inhibitors of the xiap/caspase-3 interaction. Chem. Biol. 2003, 10, 759-767. [CrossRef]
174. Bai, L.; Chen, J.; McEachern, D.; Liu, L.; Zhou, H.; Aguilar, A.; Wang, S. BM-1197: A novel and specific bcl-2/bcl-xl inhibitor inducing complete and long-lasting tumor regression in vivo. PLoS ONE 2014, 9. [CrossRef] [PubMed]
175. Aguilar, A.; Zhou, H.; Chen, J.; Liu, L.; Bai, L.; McEachern, D.; Yang, C.Y.; Meagher, J.; Stuckey, J.; Wang, S. A potent and highly efficacious bcl-2/bcl-xl inhibitor. J. Med. Chem. 2013, 56, 3048-3067. [CrossRef] [PubMed]
176. Ling, X.; Cao, S.; Cheng, Q.; Keefe, J.T.; Rustum, Y.M.; Li, F. A novel small molecule FL118 that selectively inhibits survivin, mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity. PLoS ONE 2012, 7. [CrossRef] [PubMed]
177. Melkko, S.; Mannocci, L.; Dumelin, C.E.; Villa, A.; Sommavilla, R.; Zhang, Y.; Grutter, M.G.; Keller, N.; Jermutus, L.; Jackson, R.H.; et al. Isolation of a small-molecule inhibitor of the antiapoptotic protein bcl-xl from a DNA-encoded chemical library. ChemMedChem 2010, 5, 584-590. [CrossRef] [PubMed]
178. Lin, J.; Zheng, Z.; Li, Y.; Yu, W.; Zhong, W.; Tian, S.; Zhao, F.; Ren, X.; Xiao, J.; Wang, N.; et al. A novel bcl-xl inhibitor z36 that induces autophagic cell death in hela cells. Autophagy 2009, 5, 314-320. [CrossRef] [PubMed]
179. Wang, S.; Wang, X.; Du, Z.; Liu, Y.; Huang, D.; Zheng, K.; Liu, K.; Zhang, Y.; Zhong, X.; Wang, Y. SNX-25a, a novel hsp90 inhibitor, inhibited human cancer growth more potently than 17-AAG. Biochem. Biophys. Res. Commun. 2014, 450, 73-80. [CrossRef] [PubMed]
180. Ponassi, R.; Biasotti, B.; Tomati, V.; Bruno, S.; Poggi, A.; Malacarne, D.; Cimoli, G.; Salis, A.; Pozzi, S.; Miglino, M.; et al. A novel Bim-BH3-derived bcl-XL inhibitor: Biochemical characterization, in vitro, in vivo and ex-vivo anti-leukemic activity. Cell Cycle 2008, 7, 3211-3224. [CrossRef] [PubMed]
181. Burlison, J.A.; Neckers, L.; Smith, A.B.; Maxwell, A.; Blagg, B.S. Novobiocin: Redesigning a DNA gyrase inhibitor for selective inhibition of hsp90. J. Am. Chem. Soc. 2006, 128, 15529-15536. [CrossRef] [PubMed]
182. Shoemaker, A.R.; Oleksijew, A.; Bauch, J.; Belli, B.A.; Borre, T.; Bruncko, M.; Deckwirth, T.; Frost, D.J.; Jarvis, K.; Joseph, M.K.; et al. A small-molecule inhibitor of bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Res. 2006, 66, 8731-8739. [CrossRef] [PubMed]
183. Zhao, Q.; Wu, C.Z.; Lee, J.K.; Zhao, S.R.; Li, H.M.; Huo, Q.; Ma, T.; Zhang, J.; Hong, Y.S.; Liu, H. Anticancer effects of the hsp90 inhibitor 17-demethoxy-reblastatin in human breast cancer MDA-MB-231 cells. J. Microbiol. Biotechnol. 2014, 24, 914-920. [PubMed]
184. Broome, H.E.; Yu, A.L.; Diccianni, M.; Camitta, B.M.; Monia, B.P.; Dean, N.M. Inhibition of bcl-xl expression sensitizes t-cell acute lymphoblastic leukemia cells to chemotherapeutic drugs. Leuk. Res. 2002, 26, 311-316. [CrossRef]
185. Stenderup, K.; Rosada, C.; Gavillet, B.; Vuagniaux, G.; Dam, T.N. DEBIO 0932, a new oral hsp90 inhibitor, alleviates psoriasis in a xenograft transplantation model. Acta Derm. Venereol. 2014, 94, 672-676. [CrossRef] [PubMed]
186. Wacheck, V.; Selzer, E.; Gunsberg, P.; Lucas, T.; Meyer, H.; Thallinger, C.; Monia, B.P.; Jansen, B. Bcl-x(l) antisense oligonucleotides radiosensitise colon cancer cells. Br. J. Cancer 2003, 89, 1352-1357. [CrossRef] [PubMed]
187. Chandarlapaty, S.; Sawai, A.; Ye, Q.; Scott, A.; Silinski, M.; Huang, K.; Fadden, P.; Partdrige, J.; Hall, S.; Steed, P.; et al. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against her kinase-dependent cancers. Clin. Cancer Res. 2008, 14, 240-248. [CrossRef] [PubMed]
188. Yin, H.; Lee, G.I.; Sedey, K.A.; Kutzki, O.; Park, H.S.; Orner, B.P.; Ernst, J.T.; Wang, H.G.; Sebti, S.M.; Hamilton, A.D. Terphenyl-based Bak BH3 α-helical proteomimetics as low-molecular-weight antagonists of bcl-xl. J. Am. Chem. Soc. 2005, 127, 10191-10196. [CrossRef] [PubMed]
189. Fotsop, D.F.; Roussi, F.; Leverrier, A.; Breteche, A.; Gueritte, F. Biomimetic total synthesis of meiogynin a, an inhibitor of bcl-xl and bak interaction. J. Org. Chem. 2010, 75, 7412-7415. [CrossRef] [PubMed]
190. Woodhead, A.J.; Angove, H.; Carr, M.G.; Chessari, G.; Congreve, M.; Coyle, J.E.; Cosme, J.; Graham, B.; Day, P.J.; Downham, R.; et al. Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydrois oindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone hsp90 by fragment based drug design. J. Med. Chem. 2010, 53, 5956-5969. [CrossRef] [PubMed]
191. Fogliatto, G.; Gianellini, L.; Brasca, M.G.; Casale, E.; Ballinari, D.; Ciomei, M.; Degrassi, A.; De Ponti, A.; Germani, M.; Guanci, M.; et al. NMS-E973, a novel synthetic inhibitor of hsp90 with activity against multiple models of drug resistance to targeted agents, including intracranial metastases. Clin. Cancer Res. 2013, 19, 3520-3532. [CrossRef] [PubMed]
192. Rudin, C.M.; Hann, C.L.; Garon, E.B.; Ribeiro de Oliveira, M.; Bonomi, P.D.; Camidge, D.R.; Chu, Q.; Giaccone, G.; Khaira, D.; Ramalingam, S.S.; et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin. Cancer Res. 2012, 18, 3163-3169. [CrossRef] [PubMed]
193. Bhat, R.; Tummalapalli, S.R.; Rotella, D.P. Progress in the discovery and development of heat shock protein 90 (hsp90) inhibitors. J. Med. Chem. 2014, 57, 8718-8728. [CrossRef] [PubMed]
194. Souers, A.J.; Leverson, J.D.; Boghaert, E.R.; Ackler, S.L.; Catron, N.D.; Chen, J.; Dayton, B.D.; Ding, H.; Enschede, S.H.; Fairbrother, W.J.; et al. ABT-199, a potent and selective bcl-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 2013, 19, 202-208. [CrossRef] [PubMed]
195. Vassallo, A.; Vaccaro, M.C.; De Tommasi, N.; Dal Piaz, F.; Leone, A. Identification of the plant compound geraniin as a novel hsp90 inhibitor. PLoS ONE 2013, 8. [CrossRef]
196. Ono, N.; Yamazaki, T.; Nakanishi, Y.; Fujii, T.; Sakata, K.; Tachibana, Y.; Suda, A.; Hada, K.; Miura, T.; Sato, S.; et al. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers. Cancer Sci. 2012, 103, 342-349. [CrossRef] [PubMed]
197. Chen, J.; Zhou, H.; Aguilar, A.; Liu, L.; Bai, L.; McEachern, D.; Yang, C.Y.; Meagher, J.L.; Stuckey, J.A.; Wang, S. Structure-based discovery of BM-957 as a potent small-molecule inhibitor of bcl-2 and bcl-xl capable of achieving complete tumor regression. J. Med. Chem. 2012, 55, 8502-8514. [CrossRef] [PubMed]
198. Khandelwal, A.; Hall, J.A.; Blagg, B.S. Synthesis and structure-activity relationships of EGCG analogues, a recently identified hsp90 inhibitor. J. Org. Chem. 2013, 78, 7859-7884. [CrossRef] [PubMed]
199. Chauhan, D.; Velankar, M.; Brahmandam, M.; Hideshima, T.; Podar, K.; Richardson, P.; Schlossman, R.; Ghobrial, I.; Raje, N.; Munshi, N.; et al. A novel bcl-2/bcl-x(l)/bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene 2007, 26, 2374-2380. [CrossRef] [PubMed]
200. Margarucci, L.; Monti, M.C.; Cassiano, C.; Mozzicafreddo, M.; Angeletti, M.; Riccio, R.; Tosco, A.; Casapullo, A. Chemical proteomics-driven discovery of oleocanthal as an hsp90 inhibitor. Chem. Commun. 2013, 49, 5844-5846. [CrossRef]
201. Lyman, S.K.; Crawley, S.C.; Gong, R.; Adamkewicz, J.I.; McGrath, G.; Chew, J.Y.; Choi, J.; Holst, C.R.; Goon, L.H.; Detmer, S.A.; et al. High-content, high-throughput analysis of cell cycle perturbations induced by the hsp90 inhibitor xl888. PLoS ONE 2011, 6. [CrossRef]
202. Best, O.G.; Singh, N.; Forsyth, C.; Mulligan, S.P. The novel hsp-90 inhibitor SNX7081 is significantly more potent than 17-AAG against primary cll cells and a range of haematological cell lines, irrespective of lesions in the tp53 pathway. Br. J. Haematol. 2010, 151, 185-188. [CrossRef] [PubMed]
203. Menezes, D.L.; Taverna, P.; Jensen, M.R.; Abrams, T.; Stuart, D.; Yu, G.K.; Duhl, D.; Machajewski, T.; Sellers, W.R.; Pryer, N.K.; et al. The novel oral hsp90 inhibitor NVP-HSP990 exhibits potent and broad-spectrum antitumor activities in vitro and in vivo. Mol. Cancer Ther. 2012, 11, 730-739. [CrossRef] [PubMed]
204. He, Y.; Li, Y.; Zhang, S.; Perry, B.; Zhao, T.; Wang, Y.; Sun, C. Radicicol, a heat shock protein 90 inhibitor, inhibits differentiation and adipogenesis in 3T3-L1 preadipocytes. Biochem. Biophys. Res. Commun. 2013, 436, 169-174. [CrossRef] [PubMed]
205. Oost, T.K.; Sun, C.; Armstrong, R.C.; Al-Assaad, A.S.; Betz, S.F.; Deckwerth, T.L.; Ding, H.; Elmore, S.W.; Meadows, R.P.; Olejniczak, E.T.; et al. Discovery of potent antagonists of the antiapoptotic protein xiap for the treatment of cancer. J. Med. Chem. 2004, 47, 4417-4426. [CrossRef] [PubMed]
206. Liston, P.; Fong, W.G.; Kelly, N.L.; Toji, S.; Miyazaki, T.; Conte, D.; Tamai, K.; Craig, C.G.; McBurney, M.W.; Korneluk, R.G. Identification of XAF1 as an antagonist of xiap anti-caspase activity. Nat. Cell Biol. 2001, 3, 128-133. [CrossRef] [PubMed]
207. Ju, H.Q.; Xiang, Y.F.; Xin, B.J.; Pei, Y.; Lu, J.X.; Wang, Q.L.; Xia, M.; Qian, C.W.; Ren, Z.; Wang, S.Y.; et al. Synthesis and in vitro anti-HSV-1 activity of a novel hsp90 inhibitor BJ-B11. Bioorg. Med. Chem. Lett. 2011, 21, 1675-1677. [CrossRef] [PubMed]
208. Schimmer, A.D.; Welsh, K.; Pinilla, C.; Wang, Z.; Krajewska, M.; Bonneau, M.J.; Pedersen, I.M.; Kitada, S.; Scott, F.L.; Bailly-Maitre, B.; et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell 2004, 5, 25-35. [CrossRef]
209. Nakashima, T.; Ishii, T.; Tagaya, H.; Seike, T.; Nakagawa, H.; Kanda, Y.; Akinaga, S.; Soga, S.; Shiotsu, Y. New molecular and biological mechanism of antitumor activities of KW-2478, a novel nonansamycin heat shock protein 90 inhibitor, in multiple myeloma cells. Clin. Cancer Res. 2010, 16, 2792-2802. [CrossRef] [PubMed]
210. Kim, S.H.; Bajji, A.; Tangallapally, R.; Markovitz, B.; Trovato, R.; Shenderovich, M.; Baichwal, V.; Bartel, P.; Cimbora, D.; McKinnon, R.; et al. Discovery of (2S)-1-[4-(2-{6-amino-8-[(6-bromo-1,3-benzodioxol-5-yl) sulfanyl]-9h-purin-9-yl}et hyl)piperidin-1-yl]-2-hydroxypropan-1-one (MPC-3100), a purine-based hsp90 inhibitor. J. Med. Chem. 2012, 55, 7480-7501. [CrossRef] [PubMed]
211. Lee, F.A.; Zee, B.C.; Cheung, F.Y.; Kwong, P.; Chiang, C.L.; Leung, K.C.; Siu, S.W.; Lee, C.; Lai, M.; Kwok, C.; et al. Randomized phase II study of the X-linked inhibitor of apoptosis (XIAP) antisense AEG35156 in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC). Am. J. Clin. Oncol. 2014. [CrossRef] [PubMed]
212. Sessa, C.; Shapiro, G.I.; Bhalla, K.N.; Britten, C.; Jacks, K.S.; Mita, M.; Papadimitrakopoulou, V.; Pluard, T.; Samuel, T.A.; Akimov, M.; et al. First-in-human phase I dose-escalation study of the hsp90 inhibitor auy922 in patients with advanced solid tumors. Clin. Cancer Res. 2013, 19, 3671-3680. [CrossRef] [PubMed]
213. Nikolovska-Coleska, Z.; Xu, L.; Hu, Z.; Tomita, Y.; Li, P.; Roller, P.P.; Wang, R.; Fang, X.; Guo, R.; Zhang, M.; et al. Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database. J. Med. Chem. 2004, 47, 2430-2440. [CrossRef] [PubMed]
214. Pacey, S.; Wilson, R.H.; Walton, M.; Eatock, M.M.; Hardcastle, A.; Zetterlund, A.; Arkenau, H.T.; Moreno-Farre, J.; Banerji, U.; Roels, B.; et al. A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors. Clin. Cancer Res. 2011, 17, 1561-1570. [CrossRef] [PubMed]
215. Reddy, N.; Voorhees, P.M.; Houk, B.E.; Brega, N.; Hinson, J.M., Jr.; Jillela, A. Phase I trial of the hsp90 inhibitor PF-04929113 (SNX5422) in adult patients with recurrent, refractory hematologic malignancies. Clin. Lymphoma Myeloma Leuk. 2013, 13, 385-391. [CrossRef] [PubMed]
216. Flygare, J.A.; Beresini, M.; Budha, N.; Chan, H.; Chan, I.T.; Cheeti, S.; Cohen, F.; Deshayes, K.; Doerner, K.; Eckhardt, S.G.; et al. Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). J. Med. Chem. 2012, 55, 4101-4113. [CrossRef] [PubMed]
217. Dickson, M.A.; Okuno, S.H.; Keohan, M.L.; Maki, R.G.; D’Adamo, D.R.; Akhurst, T.J.; Antonescu, C.R.; Schwartz, G.K. Phase II study of the hsp90-inhibitor BIIB021 in gastrointestinal stromal tumors. Ann. Oncol. 2013, 24, 252-257. [CrossRef] [PubMed]
218. Pacey, S.; Gore, M.; Chao, D.; Banerji, U.; Larkin, J.; Sarker, S.; Owen, K.; Asad, Y.; Raynaud, F.; Walton, M.; et al. A phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma. Investig. New Drugs 2012, 30, 341-349. [CrossRef] [PubMed]
219. Dhuria, S.; Einolf, H.; Mangold, J.; Sen, S.; Gu, H.; Wang, L.; Cameron, S. Time-dependent inhibition and induction of human cytochrome P4503A4/5 by an oral iap antagonist, LCL161, in vitro and in vivo in healthy subjects. J. Clin. Pharmacol. 2013, 53, 642-653. [CrossRef] [PubMed]
220. Jhaveri, K.; Chandarlapaty, S.; Lake, D.; Gilewski, T.; Robson, M.; Goldfarb, S.; Drullinsky, P.; Sugarman, S.; Wasserheit-Leiblich, C.; Fasano, J.; et al. A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer. Clin. Breast Cancer 2014, 14, 154-160. [CrossRef] [PubMed]
221. Asano, M.; Hashimoto, K.; Saito, B.; Shiokawa, Z.; Sumi, H.; Yabuki, M.; Yoshimatsu, M.; Aoyama, K.; Hamada, T.; Morishita, N.; et al. Design, stereoselective synthesis, and biological evaluation of novel tri-cyclic compounds as inhibitor of apoptosis proteins (IAP) antagonists. Bioorg. Med. Chem. 2013, 21, 5725-5737. [CrossRef] [PubMed]
222. Oh, W.K.; Galsky, M.D.; Stadler, W.M.; Srinivas, S.; Chu, F.; Bubley, G.; Goddard, J.; Dunbar, J.; Ross, R.W. Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer. Urology 2011, 78, 626-630. [CrossRef] [PubMed]
223. Abd-Elrahman, I.; Hershko, K.; Neuman, T.; Nachmias, B.; Perlman, R.; Ben-Yehuda, D. The inhibitor of apoptosis protein livin (ML-IAP) plays a dual role in tumorigenicity. Cancer Res. 2009, 69, 5475-5480. [CrossRef] [PubMed]